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Introduction: Soluble mesothelin (SM), megakaryocyte potentiat-
ing factor (MPF), and osteopontin (OPN) are blood biomarkers of
mesothelioma. This study evaluates their use as markers of response
to therapy and outcome.
Methods: Sixty-two patients with malignant pleural mesothelioma
were included in an observational multicenter study. Blood samples
and matched computed tomography scans were collected at diagno-
sis and, when possible, during and after therapy. For each patient,
the best overall radiological response was compared with the
changes in serum SM, MPF, and plasma OPN levels across corre-
sponding time points.
Results: In five patients, blood sampling was done shortly before
and after extrapleural pneumonectomy. SM and MPF levels mark-
edly decreased after surgery, whereas OPN levels showed a median
increase. Fifty-seven patients were surveilled during (and after)
chemotherapy, of whom 27 (47%) had stable disease, 14 (25%)
partial response, and 16 (28%) progressive disease. In patients with
stable disease, SM and MPF levels did not change significantly
across the corresponding time points, whereas OPN levels signifi-
cantly decreased. In those with partial response, SM and MPF levels
significantly decreased, whereas OPN levels showed no significant
change. In patients with progressive disease, all three biomarker
levels significantly increased. Patient responses correlated with a
15% change in all three biomarkers, although SM and MPF ap-
peared more accurate than OPN. Low baseline OPN levels were
independently associated with favorable progression-free survival
and overall survival. Neither SM nor MPF showed prognostic value.
Conclusions: SM and MPF levels were more closely associated
with disease course than OPN and might prove useful in monitoring
patient response in mesothelioma. Baseline OPN levels were an
independent negative predictor of survival. These promising results
require further validation.
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Malignant mesothelioma is a fatal asbestos-related ma-lignancy, predominantly arising from the surface sero-
sal cells of the pleura. The natural history of mesothelioma
results in a median survival of 7 to 9 months.1 When treated
with standard of care chemotherapy, an antifolate (pem-
etrexed or raltitrexed) and a platinum agent, median survival
is approximately 1 year.2,3 Highly selected patients with
early-stage epithelioid disease, treated with extrapleural
pneumonectomy (EPP), either alone or in combination with
chemotherapy and/or radiation therapy, have a median sur-
vival of up to 2 years.4
Several novel anticancer drugs are currently evaluated
in clinical trials, with tumor shrinkage being the standard end
point to evaluate their efficacy. The ability to reproducibly
measure tumor response consequently plays a pivotal role in
cancer therapy research.1,5 In patients with mesothelioma,
this, however, is troublesome. The RECIST, the standard
method for radiological response assessment,6 is not adequate
for this malignancy, as mesothelioma often presents as a rind
around the lungs, rather than as a spherical mass.5 An adjust-
ment of these criteria, i.e., “the modified RECIST,”7 has only
in part addressed this concern and still displays a low inter-
observer agreement.8 An additional limitation of radiological
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assessment, inherent to mesothelioma, is the presence of
pleural fluid and benign asbestos-related lesions.
A blood biomarker, which accurately reflects disease
course, would be a useful and relatively cheap adjunct to
monitor patient response. In mesothelioma, soluble mesothe-
lin (SM), megakaryocyte potentiating factor (MPF), and os-
teopontin (OPN) are currently the most promising blood
biomarkers,9–11 and the primary candidates for such purpose.
Both SM and MPF originate from the mesothelin gene, which
is overexpressed in epithelioid mesothelioma cells.12 The
Mesomark™ enzyme-linked immunosorbent assay (ELISA),
commonly used to measure SM in serum, was approved in
2007 by the US Food and Drug Administration to aid in the
monitoring of patients with epithelioid or biphasic mesothe-
lioma.13 Despite this approval and the recent studies which
demonstrate the potential of SM as a marker of response,14–16
this biomarker is not commonly used in clinical practice. For
OPN, a recent study found no association between plasma
levels and response in mesothelioma, whereas others do
report a correlation with disease recurrence in lung and
ovarian cancer.17,18 MPF has not yet been extensively studied
as a marker of response.
SM, MPF, and OPN could also improve therapeutic
decision making as prognostic markers. For SM, different
studies previously found that baseline serum levels are an
independent negative predictor of overall survival,16,19–21
whereas others failed to do so.22,23 For MPF, no data are
currently available. For OPN, tumor expression and blood
levels are associated with poor outcome or an aggressive
phenotype in a variety of malignancies, including mesotheli-
oma,20,24 but extensive validation is absent. The association
of SM, MPF, and OPN with progression-free survival in
mesothelioma has not been previously assessed.
This prospective multicenter study aimed (a) to exam-
ine whether changes in SM, MPF, and OPN levels reflect the
response to therapy in patients with mesothelioma and (b) to
assess whether baseline biomarker levels have a prognostic
value for progression-free survival and overall survival.
METHODS
Participants
Between January 2007 and December 2010, patients
with malignant pleural mesothelioma, scheduled for further
treatment, were included at diagnosis in an observational
multicenter study. Diagnosis was based on pleural biopsies
and validated by the pathologists of the Belgian Mesotheli-
oma Panel. Age, sex, serum C-reactive protein (CRP) levels,
performance status (PS), tumor stage, and histology were
recorded at inclusion. Blood sampling was done at inclusion,
and, when possible, at each visit during and after therapy,
until either progressive disease (PD) or death occurred. Pa-
tients’ renal function was monitored with serum creatinine
measurements. All chest computed tomography (CT) scans
made between inclusion and last blood sampling were en-
coded and collected. Tumor staging was done according to
the guidelines of the International Mesothelioma Interest
Group, which are approved by the International Union
Against Cancer.25 Serum and plasma were stored in aliquots
at 80°C. This study was approved by the ethics committee
of all participating hospitals. Written informed consent was
obtained from all participants before inclusion. The baseline
SM and MPF levels of these participants have recently been
reported in a study, which compared the diagnostic accuracy
of both biomarkers.11
Biomarker Assays
SM (nmol/L) and MPF levels (ng/ml) were measured in
serum using the Mesomark™ (Cis bio International, Gif sur
Yvette, France) and Human MPF ELISA kit (Medical &
Biological Laboratories, Nagano, Japan),26 respectively. OPN
levels (ng/ml) were measured in plasma with the Human
Osteopontin ELISA™ (Immunobiological Laboratories,
Hamburg, Germany). Assays were run according to manu-
facturer’s instructions, blinded to patient data.
Radiological and Biomarker Response
Two experienced thoracic radiologists independently
assessed the radiological responses with the modified RE-
CIST.7,8 Conflicts were solved by consensus, blinded to the
biomarker results. Depending on the number of available
CTs, one or more time point responses were recorded per
patient, each delimiting a certain time interval during follow-
up. Each CT had a matched blood sample, thus allowing to
compare the radiological response with the relative and ab-
solute changes in SM, MPF, and OPN levels across the
corresponding time points. To ensure a relevant association,
the time between CT and blood sample had to be less than 3
weeks. For each patient, the best overall radiological response
since the start of treatment was recorded.27
Statistical Analysis
Continuous variables were reported with their median
and 25th to 75th percentile values. Correlation between
baseline biomarker levels was assessed with the nonparamet-
ric Spearman rank test. Patients who had pre- and postsurgery
samples available were discussed separately in a descriptive
manner, as their small number did not allow for robust
statistical analysis. In the group of patients who received
(neoadjuvant) chemotherapy, the relationship between patient
response and the corresponding biomarker changes was eval-
uated with a number of exploratory analyses.
First, patients were stratified according to their best
overall radiological response: stable disease (SD), partial
response (PR), or PD. For each of these responses, the
Wilcoxon signed-rank test assessed whether the differences
in median biomarker levels across the corresponding time
points differed significantly from 0. Second, patients were
stratified according to their best overall response and the
relative biomarker change: a decrease 15%, a change less
than 15% (stable), or an increase 15%. Fisher’s exact test
subsequently evaluated whether a significant association was
present between these two variables. The 15% threshold was
chosen to avoid interference with the ELISA variance, which
can be up to 12%.11,28 Third, the sensitivity and specificity of
a relative biomarker change for a specific response were
evaluated. To differentiate patients with PR from those with
SD and PD, the threshold was set at a decrease 15%; to
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distinguish patients with SD from those with PR and PD, the
threshold was a change less than 15%; and to discriminate
patients with PD from SD and PR, an increase 15% was
applied. Finally, as an illustration, all available time point re-
sponses during follow-up (in addition to the best overall re-
sponses) were plotted against the corresponding relative SM,
MPF, and OPN changes in waterfall plots.
Progression-free survival and overall survival analyses
were performed with univariate and multivariate Cox propor-
tional hazards regression. Progression-free survival was de-
fined as the number of days from date of inclusion until PD.
Patients still alive and without PD were censored on the date
of the last available CT. Of note, this follow-up exceeded the
period of blood sampling. Overall survival was defined as the
number of days from date of inclusion until death. Patients
who were alive at February 1, 2011, were censored on that
date. For the continuous biomarker levels, the threshold which
best differentiated those with poor from those with favorable
prognosis was searched with an algorithm of maximization of
hazards ratio (HR)29 and evaluated with Kaplan-Meier and
log-rank statistics. All hypothesis tests were performed two
sided at the 5% significance level. Statistical analyses were done
with SPSS (version 17, SPSS Inc., Chicago, IL) and SAS
(version 9.2, SAS Institute Inc., Cary, NC).
RESULTS
Participants
In total, 62 patients with malignant pleural mesotheli-
oma were included (53 males and 9 females). Patients had a
median age of 64 years (59–72 years) and a median CRP
level of 2.11 mg/dl (0.50–8.00 mg/dl). Forty-eight patients
were treated with combination chemotherapy only (pem-
etrexed and a platinum agent), whereas the 14 others received
a multimodality therapy: neoadjuvant chemotherapy (pem-
etrexed and a platinum agent) and EPP, with or without
postoperative radiation therapy. In 5 of these 14 patients
(four epithelioid and one sarcomatoid subtype), a pre- and
post-EPP blood sample was available, whereas the nine
others were only surveilled during neoadjuvant chemother-
apy. In 43 of the 62 patients, follow-up was only available
during (a part of) the therapy, whereas in the 19 others,
control visits were also included. Median follow-up period
with blood sampling and CTs was 3.5 months (2.2–6.3
months), during which patients received a median of four
chemo cycles (2–6 cycles). Forty-three of the 62 patients
received cisplatin as platinum agent, whereas the 19 others
had carboplatin. Based on the serum creatinine levels,
none of the patients presented nephrotoxicity. Additional
characteristics are displayed in Table 1.
Biomarker Levels at a Baseline
At diagnosis, patients had a median SM level of 1.98
nmol/L (1.25–4.72 nmol/L), a median MPF level of 15.26
ng/ml (8.83–36.07 ng/ml), and a median OPN level of 868.32
ng/ml (652.19–1209.20 ng/ml). Baseline SM and MPF were
highly correlated (r  0.90, p  0.001), whereas neither of
them significantly correlated with OPN (rSM  0.23, pSM 
0.07; rMPF  0.23, pMPF  0.07). All three biomarkers had
significantly lower levels in patients with stage I disease,
compared with those with stages II to IV (p  0.05). Bio-
marker levels did not differ according to PS (0 versus 1–3)
(data not shown).
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FIGURE 1. Biomarker levels before and after ex-
trapleural pneumonectomy (EPP). In all five pa-
tients with mesothelioma, soluble mesothelin
(SM) and megakaryocyte potentiating factor
(MPF) levels decreased after surgery. Osteopontin
(OPN) levels increased in four of the five individu-
als. Four patients had an epithelioid histology,
whereas the patient with the lowest pre-EPP bio-
marker levels had a sarcomatoid subtype.
TABLE 1. Baseline Demographics of the 62 Patients with
Malignant Pleural Mesothelioma
Therapy Regimen Covariates n
Chemotherapy (n  48) Stage I 15
II–IV 33
PS 0 17
1–3 31
Histology Epithelioid 47
Biphasic 1
Multimodality (n  14) Stage II 9
III 5
PS 0 6
1–2 8
Histology Epithelioid 12
Sarcomatoid 1
Biphasic 1
PS, performance status.
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Biomarker Levels After EPP
SM and MPF levels decreased in all five patients after
EPP, resulting in a median fall of 78% (49–83%) and 76%
(40–78%), respectively (Figure 1). In contrast, OPN levels
increased in four patients, resulting in a median rise of 20%
(15–22%). In the one patient with a sarcomatoid histology,
biomarker changes were only modest: 21% for SM, 11%
for MPF, and 13% for OPN. Median time between the EPP
and the pre- and postsurgery sample was 21 days (13–22
days) and 36 days (33–50 days), respectively. Longitudinal
postsurgery biomarker measurements were available in one
patient with an epithelioid subtype and showed that OPN
levels, after the initial increase, substantially decreased 8.6
months after EPP (Figure 2). Furthermore, after the initial
decrease in all three biomarkers, levels steadily increased and
peaked approximately 2 years after EPP, when disease recur-
rence was radiologically established.
Radiological Response and Biomarker Change
Of the 57 patients who were surveilled during (and
after) chemotherapy, 27 (47%) had SD as best overall radio-
logical response, 14 (25%) PR, and 16 (28%) PD. In the
patients with SD, SM and MPF levels did not significantly
change across the corresponding time points, whereas OPN
levels significantly decreased (Table 2). In those with PR, SM
and MPF levels significantly decreased, whereas OPN levels
did not change significantly. In the patients with PD, all three
biomarker levels significantly increased, although the relative
increase in OPN levels was modest, compared with SM and
MPF. Fisher’s exact test demonstrated a significant associa-
tion between the best overall responses and a 15% change
in, respectively, SM, MPF, and OPN levels (pSM  0.001,
pMPF  0.001, pOPN  0.05). Relative changes in SM and
MPF levels, however, displayed a higher accuracy for SD,
PR, and PD, than OPN (Table 3).
When considering all available follow-up data, a total
of 125 time point responses were recorded, including 70 SD
(56%), 26 PR (23%), and 29 PD (21%). Twenty-three pa-
tients had one time point response, 15 patients had two, six
patients had three, 11 patients had four, and two patients had
five. The median duration of a time interval was 2.1 months
(1.4–3.5 months). The resulting waterfall plots again illus-
trated the lower accuracy of OPN compared with SM and
MPF (Figure 3). Time intervals with PD and PR virtually all
displayed an increase and decrease, respectively, in SM and
MPF levels, although not all changes reached the 15% thresh-
old. In time intervals with SD, the distribution of the relative
biomarker changes was more dispersed, but the majority had
stable or decreased biomarker levels, as illustrated in the
online available waterfall plots of SM, MPF, and OPN
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FIGURE 2. Longitudinal follow-up after extrapleural
pneumonectomy (EPP) of one patient with biomarker
measurements. In this patient with epithelioid mesotheli-
oma, soluble mesothelin (SM), megakaryocyte potentiat-
ing factor (MPF) and, somewhat later, osteopontin (OPN)
levels decreased after EPP. Biomarker levels gradually in-
creased again and peaked when disease recurrence was
radiologically established.
TABLE 2. Relative and Absolute Biomarker Changes According to Best Overall Radiological Response of 57 Patients with
Mesothelioma
Median (P25-P75) Biomarker Difference Across
Corresponding Time Points
Stable Disease
(n  27)
Partial Response
(n  14)
Progressive Disease
(n  16)
SM Relative (%) 0.81 (7.18 to 7.29) 34.19 (63.40 to 11.92) 53.92 (17.25 to 94.34)
Absolute (nmol/L) 0.01 (0.20 to 0.11) 0.63 (3.60 to 0.31) 1.55 (0.29 to 2.67)
Wilcoxon rank test p  0.60 p  0.01 p  0.001
MPF Relative (%) 5.75 (24.91 to 8.80) 52.79 (75.98 to 26.47) 57.88 (21.58 to 147.50)
Absolute (ng/ml) 0.52 (3.40 to 0.60) 10.56 (35.91 to 4.72) 8.14 (2.92 to 24.49)
Wilcoxon rank test p  0.11 p  0.01 p  0.001
OPN Relative (%) 13.80 (30.53 to 7.38) 6.28 (28.91 to 7.61) 7.46 (2.24 to 36.06)
Absolute (ng/ml) 97.87 (360.04 to 58.04) 26.77 (344.85 to 152.07) 84.79 (23.86 to 486.87)
Wilcoxon rank test p  0.05 p  0.22 p  0.05
SM, soluble mesothelin; MPF, megakaryocyte potentiating factor; OPN, osteopontin.
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(Supplemental Figure 1, Supplemental Digital Content 1,
http://links.lww.com/JTO/A103).
Survival Analysis
The progression-free survival and overall survival anal-
yses were performed in the 48 patients who were treated with
combination chemotherapy only (Table 1). During the course
of the study, PD was recorded in 31 patients (65%), whereas
30 patients (63%) died.
Patients had an estimated median progression-free sur-
vival of 6.8 months (95% confidence interval [CI] 3.5–10.1
months). In the univariate analysis, baseline OPN and CRP
levels were significantly and inversely associated with pro-
gression-free survival. In the multivariate analysis, both re-
tained significance (Table 4). Neither SM and MPF nor PS
and tumor stage were informative for patient outcome. For
OPN, the search algorithm29 identified 862.78 ng/ml as the
optimal threshold to differentiate those with poor from those
with favorable outcome. Patients with an OPN level below
this threshold had an estimated median progression-free sur-
vival of 14.3 months (95% CI  8.5–20.1 months), whereas
the others had a median progression-free survival of only 5.6
months (95% CI  4.4–6.8 months) (p  0.01) (Figure 4A).
When this threshold was included in the multivariate model,
instead of the continuous OPN levels, it was an independent
predictor of progression-free survival (HR  2.912, 95%
CI  1.286–6.596).
Patients had an estimated median overall survival of
15.4 months (95% CI  12.6–18.3 months). In the uni-
variate analysis, advanced mesothelioma tumor stage (I
versus II–IV) and baseline OPN and CRP levels were
significant negative predictors of overall survival. In the
multivariate analysis, only OPN and CRP retained signif-
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FIGURE 3. Waterfall plot of the
relative biomarker changes across
time intervals with partial response
(A) and with progressive disease
(B). Soluble mesothelin (SM),
megakaryocyte potentiating factor
(MPF), and osteopontin (OPN) lev-
els typically decreased across the
26 time intervals with partial re-
sponse (A) and increased across the
29 time intervals with progressive
disease (B). Dotted lines at 15%
and 15% represent the thresholds
for a significant change.
TABLE 3. Accuracy of the Relative Biomarker Changes for the Best Overall Radiological Response of the 57 Patients with
Mesothelioma
Best Overall Response
Sensitivity Specificity
SM MPF OPN SM MPF OPN
Stable diseasea (n  27) 63% (17/27) 43% (13/27) 37% (10/27) 77% (23/30) 90% (27/30) 53% (16/30)
Partial responseb (n  14) 64% (9/14) 86% (12/14) 43% (6/14) 88% (38/43) 77% (33/43) 67% (29/43)
Progressive diseasec (n  16) 81% (13/16) 81% (13/16) 38% (6/16) 85% (35/41) 88% (36/41) 83% (34/41)
Threshold is set at a achange 15%, bdecrease 15%, or cincrease 15% in biomarker levels.
SM, soluble mesothelin; MPF, megakaryocyte potentiating factor; OPN, osteopontin.
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icance (Table 4). SM, MPF, and PS were not informative
for patient outcome. For OPN, the search algorithm29
identified 1141.11 ng/ml as the optimal threshold. Patients
with levels below this threshold had an estimated median
overall survival of 18.9 months (95% CI  14.6–23.1
months), whereas in the others, median overall survival
was limited to 10.1 months (95% CI  5.5–14.7 months)
(p  0.05) (Figure 4B). When this threshold was included
in the multivariate model, instead of the continuous OPN
levels, it was an independent predictor of overall survival
(HR  2.216, 95% CI  1.050–4.678).
DISCUSSION
This multicenter observational study aimed to gain
insight in the role of SM, MPF, and OPN as markers of
patient response and outcome in mesothelioma.
In agreement with previous findings, SM and MPF
levels markedly decreased shortly after EPP, illustrating their
close association with tumor bulk.9,15,30,31 Although less sub-
stantial, such decrease was also observed in a patient with a
sarcomatoid histology. As this subtype does not overexpress
mesothelin,12 this possibly indicated the presence of some
epithelioid cell nests in the tumor. In contrast, OPN levels
showed a median increase shortly after EPP. The longitudinal
follow-up of one patient, however, revealed that OPN levels
did decrease in the long run. This interesting observation was
in accordance with a recent study in patients with nonsmall
cell lung cancer.18 In their series, OPN levels decreased after
surgery, but levels shortly after surgery were much higher
than those 6 weeks later.18 According to the authors, this
highlighted the role of OPN in wound healing and tissue
remodeling.18 As such, the association between OPN and
FIGURE 4. Survival curves strati-
fied according to baseline osteo-
pontin (OPN) levels. OPN levels are
an indicator of favorable (A) pro-
gression-free survival and (B) over-
all survival.
TABLE 4. Survival Analyses in 48 Patients with Mesothelioma Who Received Chemotherapy Only
Outcome Covariates Categories
Univariate Analysis Multivariate Analysis
HR (95% CI) p HR (95% CI) p
Progression-free survival SM (nmol/L) Continuous 1.001 (0.963–1.039) 0.98 — —
MPF (ng/ml) Continuous 1.001 (0.996–1.006) 0.71 — —
OPN (ng/ml) Continuous 1.0009 (1.0001–1.0017) 0.05 1.0009 (1.0001–1.0018) 0.05
CRP (mg/dl) Continuous 1.019 (1.003–1.035) 0.05 1.018 (1.002–1.035) 0.05
Mesothelioma stage I 1.941 (0.817–4.610) 0.13 — —
PS 0 1.068 (0.495–2.304) 0.87 — —
Overall survival SM (nmol/L) Continuous 0.993 (0.958–1.030) 0.72 — —
MPF (ng/ml) Continuous 1.001 (0.996–1.005) 0.78 — —
OPN (ng/ml) Continuous 1.0009 (1.0002–1.0016) 0.05 1.0008 (1.0001–1.0015) 0.05
CRP (mg/dl) Continuous 1.022 (1.006–1.037) 0.01 1.019 (1.003–1.035) 0.05
Mesothelioma stage I 2.809 (1.129–6.986) 0.05 2.002 (0.766–5.231) 0.16
PS 0 1.039 (0.486–2.224) 0.92 — —
HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; PS, performance status; SM, Soluble mesothelin; MPF, megakaryocyte potentiating factor; OPN, osteopontin.
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tumor debulking appears to be blurred by its inflammatory
response to the surgery.
In 57 patients surveilled during (and after) chemother-
apy, the best overall radiological responses (SD, PR, or PD)
were significantly associated with relative changes in both
SM, MPF, and OPN levels. These findings were in agreement
with recent studies on SM14–16 and demonstrated that MPF
has a very similar behavior as marker of response. This was
somewhat expected, as we recently reported that both bio-
markers are highly correlated, have an equivalent diagnostic
accuracy, and a similar longitudinal behavior in asbestos-
exposed controls.11,32 For OPN, our results were in agreement
with previous findings in lung and ovarian cancer17,18 but in
contrast with a recent study in 21 patients with mesothelioma,
which found no association with patient response.15 These
conflicting results might be due to the smaller sample size in
the latter study. Compared with SM and MPF, however, OPN
was less closely associated with the radiological responses.
This was illustrated by the less marked changes in OPN levels
in patients with PR or PD, the inferior sensitivity and spec-
ificity for patient responses, and the less straightforward
waterfall plots. Our findings also indicated that, even for SM
and MPF, the accuracy of biomarker changes for radiological
response was not absolute. Although this was in part caused
by considering a 15% threshold in relative biomarker
changes, some patients with SD, for example, displayed a
marked increase in biomarker levels. This could indicate that
an increase in biomarker levels precedes the radiological
presentation of progression. In ovarian cancer, CA-125, for
example, has shown to increase several months before dis-
ease progression becomes radiologically evident.33 Another
plausible cause is radiological misclassification, considering
the current difficulties with the modified RECIST.
Altogether, the more accurate association with tumor
debulking and radiological response indicated that SM and
MPF are more suitable for routine monitoring, when com-
pared with OPN. If confirmed in larger series, SM or MPF
could be used as an adjunct to radiological monitoring in
patients with epithelioid or biphasic mesothelioma. The
choice of threshold, which differentiates stable biomarker
levels from a significant change, will hereby be important.
Two recent studies demonstrated that a change in SM levels
above 10% can already adequately reflect patient re-
sponse,14,15 whereas others proposed a 25% threshold.16 We
opted for a 15% threshold in relative biomarker changes.
Although this led to a decrease in sensitivity, it increased
specificity, hereby especially avoiding interference with the
variance of the applied ELISA, which can be up to 12%.11,28
Further study is required to establish the optimal threshold for
routine use.
Of note, several issues can lead to false-positive
changes during monitoring. First, low biomarker levels are
more subject to assay variance, and a minor absolute change
could easily lead to a high relative change. Second, we
recently found that SM and MPF levels in controls, without
evidence of malignant disease, significantly increase over
time, in part due to aging and assay variance.32 Third, SM and
MPF are both inversely associated with renal function,32,34
and chemotherapeutics such as cisplatin may cause nephro-
toxicity during monitoring,35 although this was not the case in
our series.
This study has some limitations, which require consid-
eration. Because of the observational and exploratory nature
of the study, blood sampling and CTs were not mandatory. As
a consequence, the follow-up and time between blood sam-
pling were not uniform across patients. In addition, only a
limited number of patients were followed up after completion
of the therapy. Finally, although the number of surveilled
patients in this study was one of the largest so far, it still is
relatively small. Further validation of our findings is conse-
quently required to elucidate the clinical utility of these
biomarkers in response evaluation.
In agreement with the literature, CRP levels and tumor
stage were associated with overall survival in mesothelioma.
Low baseline OPN levels were independently associated with
favorable progression-free survival and overall survival,
which adds further proof to its prognostic significance in
mesothelioma.20,24 In addition, OPN expression and blood
levels are positively correlated with tumor stage, progression,
invasion, and metastasis.36 Recent in vitro studies gave an
insight in the underlying biology and indicated that OPN
plays an important role in the multidrug resistance and
enhancement of adhesion, proliferation, and migration activ-
ities of mesothelioma cells.37,38 For SM, different studies
previously reported that baseline levels were an independent
negative predictor of overall survival,16,19–21 whereas other
studies failed to do so.22,23 In our series, neither SM nor MPF
predicted progression-free survival and overall survival.
These survival analyses, however, were based on a relatively
low number of events and lack power. As a consequence, our
negative findings for SM and MPF should be interpreted with
caution and further examined.
In conclusion, SM and MPF levels were more closely
associated with disease course than OPN and might prove
useful in monitoring patient response in mesothelioma. Low
baseline OPN levels were independently associated with
improved progression-free survival and overall survival. Fur-
ther validation of these biomarkers in larger prospective trials
is necessary to determine their clinical utility.
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